Pricing Log in Create free account

Alto Neuroscience, Inc. (ANRO) vs Prime Medicine, Inc. (PRME)

Alto Neuroscience, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Alto Neuroscience, Inc. and Prime Medicine, Inc. are of similar size ($858.2M and $807.1M). Alto Neuroscience, Inc. has the higher net margin (0.00% vs −4,613.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Alto Neuroscience, Inc. leads on 9 and Prime Medicine, Inc. on 3.

Valuation

Metric ANRO PRME Biotechnology median
P/E n/m n/m 10.60
P/S n/m 200.59 9.40
P/B 4.91 20.52 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 177.25 9.02
Earnings yield (9.62%) (23.95%) (32.88%)
Free cash flow yield (6.39%) (19.20%) (23.13%)

Profitability

Metric ANRO PRME Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (4,824.94%) 0.00%
Net margin 0.00% (4,613.11%) 0.00%
Free cash flow margin 0.00% (3,850.92%) 0.00%
Return on equity (49.17%) (373.29%) (51.96%)
Return on assets (40.90%) (71.16%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANRO PRME Biotechnology median
Revenue growth (TTM) — (17.90%) 6.76%
EPS growth (last fiscal year) 12.40% 18.18% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ANRO PRME Biotechnology median
Debt to equity 0.09 0.00 0.00
Current ratio 14.85 3.05 4.97
Net debt to EBITDA 2.40 0.88 1.01

Dividend

Metric ANRO PRME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ANRO PRME Biotechnology median
Market cap 858.22m 807.12m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack